Dabrafenib and/or Trametinib Rollover Study
Conditions
Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Rare Cancers · High Grade Glioma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Honor Health Research Institute, Scottsdale, Arizona, United States
Honor Health Research Institute, Scottsdale, Arizona, United States
Contact: Principal Investigator (Michael Gordon)National Institute Of Health, Bethesda, Maryland, United States
James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
Novartis Investigative Site, Caba, Buenos Aires, Argentina
Novartis Investigative Site, Innsbruck, Tyrol, Austria
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Copenhagen, Denmark
Novartis Investigative Site, Lyon, France
Novartis Investigative Site, Nantes, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Villejuif, France
Novartis Investigative Site, Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Hamburg, Germany
Novartis Investigative Site, Heidelberg, Germany
Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Chuo Ku, Tokyo, Japan
Novartis Investigative Site, Rotterdam, South Holland, Netherlands
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Songkhla, Hat Yai, Thailand
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals